Azevedo-Pouly Ana Clara P, Sutaria Dhruvitkumar S, Jiang Jinmai, Elgamal Ola A, Amari Foued, Allard David, Grippo Paul J, Coppola Vincenzo, Schmittgen Thomas D
College of Pharmacy, The Ohio State University, Columbus, OH, USA.
Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Funct Integr Genomics. 2017 May;17(2-3):203-212. doi: 10.1007/s10142-016-0512-1. Epub 2016 Aug 19.
Mice harboring a G12D activating Kras mutation are among the most heavily studied models in the field of pancreatic adenocarcinoma (PDAC) research. miRNAs are differentially expressed in PDAC from patients and mouse models of PDAC. To better understand the relationship that Kras activation has on miRNA expression, we profiled the expression of 629 miRNAs in RNA isolated from the pancreas of control, young, and old P48;LSL-KRAS as well as PDX-1-Cre;LSL-KRAS mice. One hundred of the differentially expressed miRNAs had increased expression in the advanced disease (old) P48;LSL-KRAS compared to wild-type mice. Interestingly, the expression of three miRNAs, miR-216a, miR-216b, and miR-217, located within a ∼30-kbp region on 11qA3.3, decreased with age (and phenotype severity) in these mice. miR-216/-217 expression was also evaluated in another acinar-specific ELa-Kras mouse model and was downregulated as well. As miR-216/-217 are acinar enriched, reduced in human PDAC and target KRAS, we hypothesized that they may maintain acinar differentiation or represent tumor suppressive miRNAs. To test this hypothesis, we deleted a 27.9-kbp region of 11qA3.3 containing the miR-216/-217 host gene in the mouse's germ line. We report that germ line deletion of this cluster is embryonic lethal in the mouse. We estimate that lethality occurs shortly after E9.5. qPCR analysis of the miR-216b and miR-217 expression in the heterozygous animals showed no difference in expression, suggesting haplosufficiency by some type of compensatory mechanism. We present the differential miRNA expression in Kras transgenic mice and report lethality from deletion of the miR-216/-217 host gene in the mouse's germ line.
携带G12D激活型Kras突变的小鼠是胰腺腺癌(PDAC)研究领域中研究最为深入的模型之一。miRNA在PDAC患者及PDAC小鼠模型中存在差异表达。为了更好地理解Kras激活与miRNA表达之间的关系,我们分析了从对照、年轻和年老的P48;LSL-KRAS以及PDX-1-Cre;LSL-KRAS小鼠胰腺中分离的RNA中629种miRNA的表达情况。与野生型小鼠相比,100种差异表达的miRNA在晚期疾病(年老)的P48;LSL-KRAS小鼠中表达增加。有趣的是,位于11qA3.3上一个约30-kbp区域内的三种miRNA,即miR-216a、miR-216b和miR-217,在这些小鼠中随年龄(及表型严重程度)增加而表达降低。在另一种腺泡特异性ELa-Kras小鼠模型中也评估了miR-216/-217的表达,其表达同样下调。由于miR-216/-217在腺泡中富集、在人类PDAC中表达降低且靶向KRAS,我们推测它们可能维持腺泡分化或代表肿瘤抑制性miRNA。为了验证这一假设,我们在小鼠种系中删除了11qA3.3上包含miR-216/-217宿主基因的一个27.9-kbp区域。我们报告该基因簇的种系缺失在小鼠中是胚胎致死性的。我们估计致死性发生在E9.5之后不久。对杂合动物中miR-216b和miR-217表达的qPCR分析显示表达无差异,提示通过某种补偿机制存在单倍剂量不足。我们展示了Kras转基因小鼠中miRNA的差异表达,并报告了小鼠种系中miR-216/-217宿主基因缺失导致的致死性。